The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Travel Stocks Suffer As UK Extends Quarantine

Fri, 14th Aug 2020 12:12

(Alliance News) - Stocks in London were shaky at midday on Friday as poor economic data from China fostered worry that it economic recovery is faltering, while travel stocks dived after the UK imposed a quarantine on people entering from France, forcing holidaymakers to rush back home to beat the weekend deadline.

In London, the blue-chip FTSE 100 index was down 131.11 points, or 2.1%, at 6,054.80 at midday. The mid-cap FTSE 250 index was off 231.02 points, or 1.3%, at 17,693.48. The AIM All-Share index was down 5.32 points, or 0.6%, at 951.48.

The Cboe UK 100 index was down 2.3% at 603.69. The Cboe 250 was down 1.4% at 15,118.68, and the Cboe Small Companies down 0.3% at 9,598.65.

Stocks in mainland Europe weren't faring much better. The CAC 40 index in Paris was down 2.1%, while the DAX 30 in Frankfurt was down 1.4%

"China was first in to the coronavirus crisis and arguably one of the first to come out of its first phase, so the fragile nature of its recovery offers an uncomfortable view of the future for other countries," said AJ Bell investment director Russ Mould.

Retail sales – a key indication of consumer sentiment – shrank by 1.1% on-year in July, falling short of forecasts and suggesting many are still reticent about going out to spend time and money, even as China appears to have the virus largely under control. The latest data follows a drop of 1.8% on-year for retail sales in June.

Meanwhile, industrial production in China grew by 4.8% in July, the same as the previous month, but below predictions of 5.2% growth.

In London, International Consolidated Airlines Group was down 5.5%. Shares in the British Airways parent were lower after the UK added France to its 14-day quarantine list.

People arriving in the UK after 0400 BST on Saturday will be required to spend 14 days in self-isolation due to rising numbers of coronavirus cases in France. The conditions also will apply to travellers returning to the UK from the Netherlands, Monaco, Malta, Turks & Caicos and Aruba.

The move, which applies throughout the UK, comes after Prime Minister Boris Johnson promised to be "absolutely ruthless" in decisions about imposing quarantine restrictions on countries.

The problem for airlines is that people's desire for a break in the sun may be outweighed by their fear of the logistical challenges of holing up for two weeks when they get back home, with decisions on which countries to add to the quarantine list often coming at short notice.

"With France being added to the quarantine list for the UK, travel & leisure is under pressure. Shares in IAG, Ryanair, Tui and EasyJet were all sharply lower as the move will force a large swathe of cancellations right at the peak of the summer holiday season for one of the largest markets for UK tourists. Half a million Brits are thought to be in France right now," noted Markets.com analyst Neil Wilson.

Irish budget carrier Ryanair Holdings was down 4.6%. UK peer easyJet was down 6.5%. Dart Group, which owns the Jet2 airline, was down 7.1%.

Anglo-German holiday operator TUI was down 5.3%.

Outside of travel stocks, Rank Group was the best mid-cap performer, up 2.4%, ahead of UK casinos being allowed to reopen on Saturday.

Casinos, bowling alleys and casinos were on the list of UK businesses that will be allowed to welcome customers back for the first time on Saturday after months of lockdown.

Hollywood Bowl Group was up 8.5%, while Ten Entertainment Group was up 3.2%.

At the other end of the FTSE 250 index, WH Smith was down 3.7%. The books and stationery retailer makes a substantial amount of its revenue from stores in airports and train stations and so also is threatened by travel restrictions.

On the AIM, Verona Pharma was up 21%. The drugmaker said the impact of Covid-19 on clinical trials in the first half has been limited.

Verona remains on track to start its Phase 3 clinical trials with ensifentrine for the treatment of chronic obstructive pulmonary disease later in 2020. It also has received a notice from US Food & Drug Administration to proceed with a study of ensifentrine in patients with Covid-19 at the University of Alabama.

In New York, the Dow Jones Industrial Average was pointed to open down 0.5%, the S&P 500 index down 0.3% and the Nasdaq Composite down 0.1%.

The pound was quoted at USD1.3094 on Friday at midday, firm from USD1.3084 at London equities close Thursday.

The euro was priced at USD1.1807, down from USD1.1830. Against the yen, the dollar was quoted at JPY106.75 in London, lower from JPY106.90.

The eurozone economy crashed 12% in the second quarter of 2020, according to figures from Eurostat on Friday.

This quarter-on-quarter decline was the worst reading since the series started in 1995. In the first three months of the year, gross domestic product fell 3.6% sequentially.

Year-on-year, the eurozone economy shrank 15% in the three months to June, again the sharpest decline seen since 1995 and a deterioration from the 3.1% fall posted for the first quarter. Two quarters in a row of contraction mean the eurozone economy has entered into recession.

In commodities, Brent oil was trading at USD44.66 a barrel Friday midday, down from USD45.18 a barrel Thursday evening in London.

Gold was quoted at USD1,950.86 an ounce at midday, slightly higher from USD1,947.60 an ounce at the London equities close Thursday.

Still to come in the economic events calendar on Friday are US retail sales figures at 1330 BST.

By Neetika Kurup; neetikakurup@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
13 Jan 2020 11:08

Verona Pharma shares surge after results from latest study

(Sharecast News) - Respiratory disease-focussed biopharmaceuticals company Verona Pharma announced positive top-line data from a four week, 416 patient phase 2b dose-ranging study evaluating nebulised ensifentrine or placebo as an add-on treatment to 'Spiriva Respimat', or tiotropium, which is a long acting anti-muscarinic bronchodilator, in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).

Read more
13 Jan 2020 10:34

UK WINNERS & LOSERS SUMMARY: Spirent Up After Lifting Profit Guidance

UK WINNERS & LOSERS SUMMARY: Spirent Up After Lifting Profit Guidance

Read more
13 Jan 2020 07:56

Verona Pharma Says Ensifentrine Study Shows Positive Results

Verona Pharma Says Ensifentrine Study Shows Positive Results

Read more
5 Nov 2019 11:29

Verona Pharma losses widen as it pours resources into ensifentrine

(Sharecast News) - Biopharmaceutical company Verona Pharma updated the market on its operations and finances for the three and nine months ended 30 September on Tuesday, highlighting positive results from the second part of its phase 2 study of the dry powder inhaler formulation of 'ensifentrine' in chronic obstructive pulmonary disorder (COPD), delivered by handheld inhaler over one week of twice-daily treatment.

Read more
5 Nov 2019 10:38

UK WINNERS & LOSERS SUMMARY: AB Foods Rises As Primark Adds US Stores

UK WINNERS & LOSERS SUMMARY: AB Foods Rises As Primark Adds US Stores

Read more
5 Nov 2019 10:15

Verona Pharma Third Quarter Loss Widens On Research & Development

Verona Pharma Third Quarter Loss Widens On Research & Development

Read more
29 Oct 2019 15:30

Inland Homes snaps up 50% stake in Cheshunt Lakeside Development

(Sharecast News) - Inland Homes on Tuesday acquired a 50% interest in joint-venture partner Cheshunt Lakeside Developments Limited that was held by CPC Group Limited.

Read more
6 Aug 2019 12:01

Verona Pharma Loss Widens In First Half On Clinical Trial Expenses

(Alliance News) - Verona Pharma PLC on Tuesday said its loss widened in the second quarter and the first half of 2019 as it progressed on clinical trials of Ensifentrine, used for the treatment of

Read more
5 Aug 2019 10:42

WINNERS & LOSERS SUMMARY: Risk-Off Trade Sends Gold Miners Higher

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - up 3.1%. The Mexican gold miner rose as the price of

Read more
5 Aug 2019 09:44

Verona Pharma Shares Jump 15% On Positive Ensifentrine Study Results

(Alliance News) - Verona Pharma PLC on Monday reported positive second phase test data for a dry powder inhaler formulation of its lead development product ensifentrine.The stock was 15% in

Read more
25 Jun 2019 15:31

Verona Pharma strengthens clinical team ahead of next round of trials

(Sharecast News) - Respiratory-focussed biopharmaceutical company Verona Pharma announced two senior appointments to its clinical team on Tuesday.

Read more
29 May 2019 16:23

Director dealings: Piers Morgan's spouse ups stake in Verona Pharma

(Sharecast News) - Verona Pharma revealed on Wednesday that chief financial officer Piers Morgan's wife Kayt Morgan had acquired 33,802 ordinary shares in the AIM-listed biotechnology outfit.

Read more
7 May 2019 14:41

Verona Pharma announces next study of nebulised ensifentrine

(Sharecast News) - Clinical-stage biopharmaceutical company Verona Pharma announced the initiation of a phase 2b dose-ranging study evaluating nebulised ensifentrine (RPL554) added on to a long-acting bronchodilator in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) on Tuesday.

Read more
9 Apr 2019 15:25

Verona Pharma Gets EU Patent For COPD Clinical Candidate Ensifentrine

LONDON (Alliance News) - Verona Pharma PLC on Tuesday said it secured a key patent from the European Patent Office relating to its lead development candidate, ensifentrine.The clinical that

Read more
9 Apr 2019 08:23

Verona Pharma gets another European patent on ensifentrine

(Sharecast News) - Respiratory disease-focussed clinical stage biopharmaceutical company Verona Pharma announced on Tuesday that the European Patent Office had granted an additional key patent relating to its lead development candidate, 'ensifentrine'.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.